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Abstract 
An isocratic reversed phase HPLC method has been developed for determination of mefenamic acid on a Grace, 
alltima C18 column (250x4.6 mm) using a mobile phase consisting of methanol : ammonium acetate (pH 6) 
(67:33 v/v) at a flow rate of 1 mL/min. Detection was carried out at 254 nm. Retention time of mefenamic acid 
was 9.85 (±0.36) mins. The method was validated with respect to specificity, linearity, accuracy, precision, 
ruggedness, and robustness.  
The proposed method is simple, precise, sensitive, and reproducible and is applicable for quantification of 
mefenamic acid in an Emulgel (topical formulation) developed and formulated in our laboratory. 
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Introduction: 
Mefenamic acid 2-[(2, 3-dimethylphenyl) amino] benzoic acid is a non-steroidal anti-inflammatory agent with 
analgesic, anti-inflammatory, and antipyretic properties
1. mefenamic acid is official in IP
2, BP
3, USP
4 and EP
5. 
Literature survey reveals the availability of several analytical methods being developed and validated for 
mefenamic acid alone or in combination with other drugs. Various methods have been developed either for bulk 
or in oral dosage form
6-11.  But no analytical method has been reported for estimation of mefenamic acid in 
topical formulation (Emulgel).The present study describes a validated isocratic RP-HPLC method for 
mefenamic acid in an Emulgel (topical formulation) developed and formulated in our laboratory. 
Materials And Methods: 
Apparatus: 
Chromatography was performed on Jasco Binary system with, two PU2080 PLUS intelligent HPLC pumps, 
UV2075 PLUS intelligent UV detector, Solvent Mixing module MX-2080-31, Rheodyne
® manual injector 
system, LCNet II / ADC system interface and Borwin
® Chromatography Software, Jasco Corporation, Japan 
and5µm Grace Alltima  C18  column having dimensions of 250 x 4.6 mm id was used. 
Materials and Reagents: 
Mefenamic acid standard was obtained as a gift sample from Flamingo Pharmaceuticals Ltd (Navi Mumbai, 
India). HPLC grade methanols, water, ammonium acetate used were purchased from S.D. Fine Chemicals 
(Mumbai, India). 
Chromatographic Conditions: 
Chromatographic separation was carried out on a Grace, Alltima, 250mm×4.6mm, 5µm C-18 reverse phase 
column. Mobile phase consisting of methanol and ammonium acetate (pH-6) was pumped at a flow rate of 1 
mL/min. The elution was monitored at 254 nm and the injection volume was 20 μL. Validation of the method 
was performed following the International Conference on Harmonization (ICH) guidelines 
12. 
Preparation of the Mobile Phase and Standard Solutions: 
Methanol and ammonium acetate used for the mobile phase were filtered through a 0.45 µm membrane filter 
(Ultipore N –66R Nylon 66; Pall Corp.,) and degassed by ultrasonication for 15 min. 
The standard Stock solution was prepared by dissolving mefenamic acid in methanol separately to get a solution 
containing1 mg /mL for mefenamic acid. The working standard solution of mefenamic acid was prepared by 
diluting 0.2 mL stock solution to 10 mL with methanol to obtain a solution containing 20µg /mL mefenamic 
acid. 
Preparation of the Sample Solutions: 
1 g of emulgel was accurately weighed in 10 mL volumetric flask. About 6 mL of methanol was added, further 
was then vortexed and sonicated for 15 minutes with intermittent swirling to get uniform dispersion. Volume 
was made up with methanol to obtain Sample Stock Solution of concentration 1000 µg/mL. This stock solution 
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solution to 10mL with methanol to obtain a solution containing 20/µg mL mefenamic acid. 
 Analysis of developed Formulation: 
Assay of developed topical formulation containing mefenamic acid (1%w/w) was performed by preparing the 
sample solutions as described earlier in the preparation of the sample. Six injections of above prepared sample 
and standard solutions were injected. The assay of the developed formulation sample was calculated by 
comparing the areas of standard and sample peaks.  
Validation of the Method: 
Calibration curve (linearity of the HPLC method): 
The calibration curve was constructed by plotting concentrations of mefenamic acid versus peak areas, and the 
regression equations were calculated. The linearity of the method was investigated by using concentrations of 5, 
10, 20, 30, 40, 50, 60µg/mL. These concentrations were prepared by diluting appropriate volumes of working 
standard with methanol. The retention time of mefenamic acid was 9.85(±0.36) mins. 
System suitability study: 
For this study, 20 µL blank solution [methanol] was injected and run for 12 mins. After this, 20 µL standard 
solutions in six replicates were injected, and the RSD of the resultant peak areas was calculated. 
Accuracy (recovery): 
Accuracy of the method was studied by recovery experiments using the standard addition method at three 
different levels (80, 100, and 120%). Known amounts of standard solutions containing mefenamic acid (8, 10, 
and 12 µg) were added to prequantified sample solutions to reach the 80, 100, and 120% levels. These samples 
were analyzed and recovery was calculated. 
 Precision (repeatability): 
Precision of the assay method was demonstrated by injecting six different sample solutions containing 
mefenamic acid equivalent to 20µg/mL and RSD of the mean assay value was calculated. 
 Intermediate precision (ruggedness): 
 Intermediate precision of the method was demonstrated by carrying out the experiment on different day, by 
different analyst, and using different C18 column. 
Robustness: 
Robustness of the method was demonstrated by deliberately changing the chromatographic conditions. The flow 
rate of the mobile phase was changed from 1.0 to 0.9 mL/min and from 1.0 to 1.1 mL/min. The composition of 
mobile phase was changed from 67:33 to 70.3:33 and from 67:33 to 64.35:33. The sample solutions described 
for the robustness study were applied onto the column in triplicate, and the responses were determined. 
 Limit of Detection (LOD) and Limit of Quantification (LOQ): 
LOD and LOQ of mefenamic acid was calculated using the following equations as per International Conference 
on Harmonization (ICH) guidelines. 
LOD = 3.3 x σ/S, LOQ = 10 x σ/S 
Where, σ = Standard deviation of response   S = Slope of regression equation. 
Specificity: 
Specificity of the method was demonstrated by injecting the blank solution, standard solution, sample solution, 
and solvent extracted placebo and the responses were determined. 
Results and Discussions: 
Several mobile phase compositions were tried. A satisfactory separation and good peak symmetry were obtained 
by using the described methanol: ammonium acetate 
(pH-6)(67:33v/v). Quantification was achieved with UV detection at 254 nm. Representative chromatograms of 
standard mefenamic acid and mefenamic acid in Emulgel (topical formulation) are shown in Figure1 and 
Figure 2 respectively. 
System suitability tests were carried out on freshly prepared standard solutions (n = 6) containing mefenamic 
acid. System suitability parameters obtained with 20 µL injection volumes are summarized in Table 1. 
Linearity regression data are summarized in Table 2, which shows A good linear relationship between 
concentration of mefenamic acid and peak areas was obtained over a concentration range of 5–60 µg/mL Figure 
3. 
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2) was found to be 0.9996 for mefenamic acid which ensures that a good correlation 
existed between the peak area and analyte concentration .The LOD was found to be 1.34µg/mL for mefenamic 
acid. LOQ was found to be 4.06 µg/mL These values indicate that the method is sensitive. 
In the precision studies, RSD of mean assay values was found to be 1.62% for mefenamic acid. These %RSD 
values which are well below 2% indicate that the repeatability of this method is satisfactory. Thus there exists a 
closeness of agreement in repeated measurements of peak response. The intermediate precision study revealed 
that the method is rugged with %RSD values of 1.96, 1.10 and 0.79 for performing the analysis by changing the 
column   and analyst and performing the analysis on another day respectively. As evident the RSD values of the 
data obtained are well below 2% indicating that method can be repeated successfully on different day, on 
different column and by different analyst. 
Accuracy studies indicated that the percent recoveries were obtained from the difference between the areas of 
spiked and unspiked samples. The mean recovery of the added standard drug was 98.80%. This means recovery 
value is well within the range of 98-100%, indicating the method is accurate. 
Specificity studies indicated good resolution was obtained between the drugs and excipients showing complete 
separation of mefenamic acid. No interference from excipients, impurities, or degradation products ensured that 
the peak response was due to mefenamic acid only. The resolution between excipient peak and mefenamic acid 
peak was found to be 3.10. 
Robustness studies signified that the results of the method remained unaffected by small, deliberate changes in 
the flow rate and mobile phase composition. The RSD of mean assay values was found to be 0.87 % with a flow 
rate of 0.9 mL/min. The RSD of mean assay values was found to be 0.80% with a flow rate of 1.1 mL/min. 
Also, RSD of mean assay values was found to be 1.27% at mobile phase composition of 70.3:33v/v and 1.28% 
at mobile phase composition of 64.3:33 v/v. The RSD values of the data obtained are well below 2% indicating 
that method is robust i.e. it is reliable during normal use. All the validation data are summarized in Table 3. 
The assay results obtained by using the proposed method for the analysis of developed Emulgel formulation 
containing mefenamic acid (1%w/w) were in good agreements with the labeled amounts of mefenamic acid. The 
average contents of mefenamic acid in developed formulation were 0.009 gm/1g (0.009% w/w). 
Conclusions: 
The proposed RP-HPLC method is accurate, precise, sensitive, selective, and rapid for the determination of 
mefenamic acid in an emulgel (topical formulation) developed and formulated in our laboratory. 
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Figures legends 
Fig. 1: Chromatogram of Standard Mefenamic Acid (R.T. 9.85 (±0.36)) at 254 nm. 
Fig. 2: Chromatogram of Mefenamic Acid in Topical Formulation (R.T. 9.9 (±1.10)) at 254 nm  
Fig. 3: Calibration Curve Diagram For Mefenamic Acid 
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Figure 2: Chromatogram of Mefenamic Acid in Topical Formulation (R.T. 9.9 (±1.10)) at 254 nm 
 
Fig. 3: Calibration Curve Diagram For Mefenamic Acid 
                                                                                                   y=41804+88511 
                                                                                                   R
2 = 0.9996    
 
 
 
 
Teena Oswal et al. / International Journal of Pharma Sciences and Research (IJPSR)
ISSN : 0975-9492 Vol 5 No 06 Jun 2014  235Tables 
Table 1. System Suitability Test Parameters For Mefenamic Acid. 
Parameter Mefenamic  Acid   
Retention  
Time(min) 
 
9.82 ±1.14   
Theoretical 
plates 
 
3284.31± 1.48 
 
 
Asymmetry 
 
1.617± 1.5 
 
 
 
 
 
Area of 
response  
1228147.51±1.56 
 
 
 
 
Table2: Regression Analysis Of Calibration Curve For Mefenamic Acid 
Parameter 
 
Mefenamic Acid   
Linearity 
range(μg/mL) 
     
 
5-60  
Regression equation 
 
y= 41804x + 88511 
Correlation 
coefficient 
(R
2) 
 
0.9996 
Slope 
 
41804  
X-intercept 
 
-2.117 
Y-intercept 
 
88511  
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Parameter  Mefenamic acid  
LOD (µg/ml)  1.34 
LOQ (µg/ml)  4.06µg/mL 
Accuracy( % recovery)  98.8 ±0.60 
Precision 95.43±1.62
a 
Ruggedness  
102.41±1.96
a  Column change 
Analyst change  95.66 ± 1.10
a 
Day change  93.93 ± 0.79
a 
Robustness (70.3:33v/v 
Mobile phase comp.) 
104.46± 1.27
b 
Robustness (64.3:33v/v 
Mobile phase comp.) 
98.17± 1.28
b 
Robustness (0.9mL/min Flow 
rate ) 
98.37±0.87
b 
Robustness (1.1mL/min Flow 
rate ) 
98.51±0.80
b 
                            a mean assay values of 6 replicates  
                           b mean assay values of 3 replicates 
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